A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

Phase 1 Completed 8 enrolled Vertex Pharmaceuticals Incorporated

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.

Timeline

Start: 2025-03-21
Primary completion: 2025-05-17
Completion: 2025-05-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VX-993	Unknown	—	Oral

Indications

No indication recorded.